Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.
Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.
Sells instruments and then earns repeatedly on the assay kits used on them, so reagent sales follow the number of samples customers run. Customers are mostly research labs, so research-grant funding affects demand.
Moat: narrow (IP / patents, process know-how). Proprietary ultra-sensitive protein detection technology differentiated from standard immunoassays.
Headquarters: Fremont, California, US · Founded: 2018 · Employees: 222
Size Alamar Biosciences (ALMR) is a United States Health Care company (Biotechnology) with a market value of $2.12B, the 1737th largest of 3,085 United States companies the cockpit tracks. Shares closed at $30.51 on 18 Nov 2026.
Performance Over six months the shares gained 51.3%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 195.2% over the last twelve months (peer median +4.1%); the operating margin is -42.2% (peer median -19.9%).
Valuation It trades at 26.1× enterprise value to sales against a peer median of 9.8× (3rd most expensive of 15).
Capital Return on invested capital runs 27.3 points below its cost of capital (6.5% WACC).
Short interest Short interest is 3.2% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $74.2M | $25.1M |
| Revenue growth | — | +195% | — |
| Gross profit | n/a | $41.7M | $8.61M |
| EBITDA | n/a | -$27.5M | -$46.4M |
| Net income | n/a | -$29.8M | -$47.1M |
| Free cash flow | n/a | -$59.0M | -$58.2M |
| Capital expenditure | n/a | $6.38M | $3.39M |
| Total debt | $42.4M | $276M | $268M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alamar Biosciences ALMR | $2.12B | +51% | +195% | -42% | 26.1× | n/a |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 6.2× | 21.3% |
| Standard BioTools LAB | n/a | -46% | n/a | n/a | n/a | n/a |
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 9.2× | 31.6% |
| Nautilus Biotechnolgy NAUT | $310M | +2% | n/a | -15,106% | 588.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALMR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.3% | -4.9% | 5th highest of 21 |
| 6-month return | +51.3% | -10.8% | 3rd highest of 20 |
| Distance from 52-week high | -23.0% | -34.1% | 7th highest of 21 |
| Revenue growth (TTM) | +195.2% | +4.1% | 3rd highest of 17 |
| Operating margin | -42.2% | -19.9% | 6th lowest of 15 |
| EV / Sales | 26.1× | 9.8× | 3rd most expensive of 15 |
| ROIC minus cost of capital | -27.3 pp | -11.0 pp | 2nd lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |